Mia Wilkinson

Translational Medicine PhD Candidate

[Stephen L. Archer @DrStephenArcher]

Congratulations to Dalia Miller https://t.co/v7c8ALkkAV TMED Candidate & mentor Dr Kim Dunham-Snary on paper in Frontiers | Preclinical models of mitochondrial dysfunction: mtDNA and nuclear-encoded regulators in diverse pathologies ⁦@queensutime⁩ https://t.co/D8AUp5iqOu

[Mia Wilkinson @MiaSWilkinson]

I am so grateful to have had the privilege of attending #SfRBM2024, and for the opportunity to share our research and connect with experts in the field. Huge thanks to @KimSnary for your support and guidance!

[Dr. Kimberly Snary @KimSnary]

#SfRBM2024 has wrapped! Team @MitoMetabLab collected their abstract/travel awards (#proudPI), and we wish to congratulate @DrEMBahnson on his Mentoring Excellence Award and Dr. Holly van Remmen, the inaugural Trailblazer Award recipient. See everyone in DC next year!

[Stephen L. Archer @DrStephenArcher]

Team TIME @Science Rendezvous ⁦@queensutime⁩ ⁦@QueensuDOM⁩ ⁦@KingstonHSC⁩ ⁦@queensualumni⁩ .The Translational Institute of Medicine scientists busy exciting young minds about science 🧬 and medicine 💊

[Mia Wilkinson @MiaSWilkinson]

Such a fun day! @sci_rendezvous @queensutime

[Stephen L. Archer @DrStephenArcher]

Team TIME @Science Rendezvous ⁦@queensutime⁩ ⁦@QueensuDOM⁩ ⁦@KingstonHSC⁩ ⁦@queensualumni⁩ .The Translational Institute of Medicine scientists busy exciting young minds about science 🧬 and medicine 💊

[Stephen L. Archer @DrStephenArcher]

Research in progress with ⁦@tmedQueens⁩ students-Mia Wilkinson (Dunham-Snary lab) presented her poster on measurement of platelet metabolism as a liquid biopsy to assess muscle metabolism in cardiometabolic syndrome (for SFRBM meeting) KUDOS Mia ⁦@QueensuCPU⁩

[Mia Wilkinson @MiaSWilkinson]

🎉🎉

[Dr. Kimberly Snary @KimSnary]

It was a big day for @MitoMetabLab. The first-ever paper written by one of my stellar trainees was submitted today! 🥳 Congratulations @MiaSWilkinson - en route to Montreal for COSC right after submission! 🤓 @tmedQueens preparing students well! #teamworkmakesthedreamwork

[Dr. Kimberly Snary @KimSnary]

Team @MitoMetabLab presenting their 'side hustles' at COSC!

They never cease to raise the bar and I am such a #proudPI 🤓

[Mia Wilkinson @MiaSWilkinson]

@tmedQueens @QueensuDOM @QueensUHealth @BethanyMonteith @LintonSophia @Asish_Dasgupta @SamanthaDelios Thanks for the great summary Sam! Would you anticipate barriers to research into cheaper drugs or drug regimens from pharmaceutical companies due to the large role they play in sponsoring clinical trials?

[Mia Wilkinson @MiaSWilkinson]

@schinhail @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth coupled with surveillance and monitoring during and after treatment. Figure 1 of this review summarizes this timeline very well:
https://t.co/mp0Nhxspzs 2/2

[Mia Wilkinson @MiaSWilkinson]

@schinhail @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Thanks for the question! I think as Dr. Abdel-Qadir alluded to, as much assessment as possible would be ideal, but barriers such as imaging wait times make this a feasibility issue. Typically, at-risk patients would have preventive measures taken before and during treatment, 1/

[Mia Wilkinson @MiaSWilkinson]

@MattiMcfarlane @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Advancements in cardio-protective therapies, such as dexrazoxane treatment before anthracycline chemotherapy, may also be a useful strategy to protect high-risk patients. 3/

[Mia Wilkinson @MiaSWilkinson]

@MattiMcfarlane @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth and those with high CVD risk are managed prior to, throughout, and after treatment (i.e. a hypertensive individual would have their hypertension managed and monitored during and after treatment). 2/

[Mia Wilkinson @MiaSWilkinson]

@MattiMcfarlane @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Thanks for your response! To answer your first question:
While some breast cancer therapies have more favourable CVD risk profiles, known cardio-toxic agents are often necessary for curative cancer treatment. Choice of therapy is dictated by tumour and patient characteristics 1/

[Mia Wilkinson @MiaSWilkinson]

@abby_mocho @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth and relay it in a way that facilitates informed decision-making. 3/3

[Mia Wilkinson @MiaSWilkinson]

@abby_mocho @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth effectively communicate these risks to patients. As I touched on in my blog post, information about treatment risks may be confusing or scary from a patient's perspective, but it is the responsibility of the physician to appropriately outline all pertinent information 2/

[Mia Wilkinson @MiaSWilkinson]

@abby_mocho @tmedQueens @LintonSophia @Asish_Dasgupta @queensutime @QueensuDOM @QueensUHealth Great question! Patient autonomy is very important, especially in a field such as oncology where many treatment options have significant adverse effects. Oncologists should be aware of the cardio-toxic effects of possible treatments they may prescribe, and be able to 1/

[Stephen L. Archer @DrStephenArcher]

Proud of my colleague, Dr Kim Dunham-Snary ⁦@QueensuDOM⁩ , who just received her official Tier 2 Canada Research Chair certificate for mitochondrial metabolic research from ⁦@JustinTrudeau⁩ -lucky to have you here ⁦@queensuResearch⁩ in DBMS & the DOM!